Trial Outcomes & Findings for Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery (NCT NCT04117074)

NCT ID: NCT04117074

Last Updated: 2026-05-19

Results Overview

Pain intensity was measured using the Visual Analog Scale (VAS), a 0-10 scale where 0 indicates no pain and 10 indicates worst pain imaginable. VAS scores were assessed hourly from 0 to 48 hours postoperatively. The area under the curve (AUC) was calculated as the sum of hourly VAS scores over 48 hours, yielding a possible range of 0 to 480. Higher scores indicate greater cumulative pain burden and worse outcomes.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

106 participants

Primary outcome timeframe

0 to 48 hours postoperatively

Results posted on

2026-05-19

Participant Flow

Patients were recruited from the gynecologic oncology service at a single academic medical center. Potentially eligible participants undergoing planned midline laparotomy will be identified through surgical schedules and clinic visits. Patients will be approached preoperatively by study personnel, and informed consent will be obtained prior to enrollment.

Participant milestones

Participant milestones
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Overall Study
STARTED
54
52
Overall Study
COMPLETED
49
50
Overall Study
NOT COMPLETED
5
2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Total
n=99 Participants
Total of all reporting groups
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=30 Participants
1 Participants
n=30 Participants
3 Participants
n=60 Participants
Age, Continuous
53.69 Years
STANDARD_DEVIATION 14.40 • n=30 Participants
59.78 Years
STANDARD_DEVIATION 12.38 • n=30 Participants
56.77 Years
STANDARD_DEVIATION 13.70 • n=60 Participants
Sex: Female, Male
Female
49 Participants
n=30 Participants
50 Participants
n=30 Participants
99 Participants
n=60 Participants
Sex: Female, Male
Male
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants
Race (NIH/OMB)
Asian
2 Participants
n=30 Participants
3 Participants
n=30 Participants
5 Participants
n=60 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants
Race (NIH/OMB)
Black or African American
8 Participants
n=30 Participants
9 Participants
n=30 Participants
17 Participants
n=60 Participants
Race (NIH/OMB)
White
37 Participants
n=30 Participants
37 Participants
n=30 Participants
74 Participants
n=60 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=30 Participants
0 Participants
n=30 Participants
0 Participants
n=60 Participants

PRIMARY outcome

Timeframe: 0 to 48 hours postoperatively

Pain intensity was measured using the Visual Analog Scale (VAS), a 0-10 scale where 0 indicates no pain and 10 indicates worst pain imaginable. VAS scores were assessed hourly from 0 to 48 hours postoperatively. The area under the curve (AUC) was calculated as the sum of hourly VAS scores over 48 hours, yielding a possible range of 0 to 480. Higher scores indicate greater cumulative pain burden and worse outcomes.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Analgesia Assessed by the Area Under the Curve of Visual Analog Scale Pain Intensity Scores
87.1 VAS score x Hours
Standard Deviation 65.4
92.8 VAS score x Hours
Standard Deviation 69.6

PRIMARY outcome

Timeframe: 0 to 48 hours postoperatively

Total opioid consumption in IV mg morphine equivalents from 0 to 48 hours postoperatively will be compared between the two arms.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Total Opioid Consumption
21.2 Morphine Miligram Equivalents
Interval 9.3 to 44.3
18.8 Morphine Miligram Equivalents
Interval 5.8 to 49.5

SECONDARY outcome

Timeframe: Days 1 through 7 post-intervention

Population: Although 49 participants were assigned to arm A, one participant withdrew immediately after surgery and did not provide any QOR-15 data.

Mean patient-perceived quality of recovery scores using the Quality of Recovery-15 instrument (QoR-15) on postoperative days 1 to 7 were compared between the two arms. The QoR-15 is a validated instrument designed to measure the major domains of postoperative recovery with a score range of 0 indicating the poorest patient-perceived quality of recovery to 150 indicating the highest patient-perceived quality of recovery. QoR-15 scores were analyzed using a linear mixed-effects model for repeated measures across postoperative days 1-7. The single value reported for each arm represents the model-based estimated marginal mean (least squares mean) across all assessed postoperative days using all available observed data without imputation. This reflects an overall POD1-7 summary rather than a score from a single postoperative day.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=48 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Patient-perceived Quality of Recovery as Assessed by the Quality of Recovery-15 Instrument (QoR-15)
106.24 Score on scale
95% Confidence Interval 3.03 • Interval 100.24 to 112.24
107.46 Score on scale
95% Confidence Interval 2.96 • Interval 101.61 to 113.32

SECONDARY outcome

Timeframe: Up to 7 days post-intervention

Time to ROBF is defined as the time lapse from the day of surgery (DOS) to the day oral intake is consistently tolerated for 48 hours without vomiting.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Time (Days) to Return of Bowel Function (ROBF)
2 days
Interval 2.0 to 3.0
3 days
Interval 2.0 to 4.0

SECONDARY outcome

Timeframe: Up to 7 days post-intervention

Ileus is defined as the occurrence of postoperative nausea and vomiting requiring cessation of oral intake and initiation of intravenous hydration +/- nasogastric tube placement following documented ROBF or the persistence of these symptoms beyond postoperative day 5 in the absence of ROBF.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Number of Participants With Postoperative Ileus
6 Participants
6 Participants

SECONDARY outcome

Timeframe: Up to 7 days post-intervention

The Johns Hopkins Highest Level of Mobility (JH-HLM) scale is an ordinal scale ranging from 1 to 8, with higher scores indicating better mobility. Scores represent observed mobility milestones achieved by the patient; a score of 1 indicates lying in bed, while a score of 8 indicates walking 250 feet or more. Mobility was analyzed using a linear mixed-effects model for repeated measures across postoperative days 1-7. The single value reported for each arm represents the model-based estimated marginal mean (least squares mean) across all assessed postoperative days using all available observed data without imputation. This reflects an overall POD1-7 summary rather than a single postoperative day.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Mobility as Assessed by the Johns Hopkins Highest Level of Mobility (JH-HLM) Scale
7.25 Score on a scale
Interval 6.8 to 7.71
7.27 Score on a scale
Interval 6.82 to 7.72

SECONDARY outcome

Timeframe: Up to 7 days post-intervention

Population: The number of participants with a sedation score ≥2 at any time from postoperative day 0 through postoperative day 7 was reported.

The Pasero Opioid-induced Sedation Scale (POSS) is a valid, reliable tool used to assess sedation when administering opioid medications to manage pain. It uses an ordinal scale of 1-4 with a POSS of 1 or 2 indicating an acceptable level of sedation and a score of 3 or 4 indicating over-sedation and the need for intervention, such as the administration of a reversal agent in the case of a score of 4.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Number of Participants With Sedation Score ≥2 as Assessed by the Pasero Opioid-Induced Sedation Scale
1 Participants
0
3 Participants
0

SECONDARY outcome

Timeframe: Up to 1 year

The duration of the index inpatient postoperative admission in days.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Length of Stay
4 Days
Interval 3.0 to 6.0
4.5 Days
Interval 3.0 to 6.0

SECONDARY outcome

Timeframe: Arrival in recovery through hospital discharge, up to 1 year

Time to diuresis is defined as the recovery time in hours to achieve a net negative fluid balance sustained over a 24 hour time period.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Time to Postoperative Diuresis
48 Hours
Interval 24.0 to 48.0
41.75 Hours
Interval 36.0 to 48.0

SECONDARY outcome

Timeframe: Arrival in recovery through hospital discharge, up to 1 year

Total intravenous fluids administered in mL.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Total Intravenous Fluids Administered in mL
2523 Milliliters
Interval 1100.0 to 3862.0
2379 Milliliters
Interval 884.0 to 4944.0

SECONDARY outcome

Timeframe: Start of operation through hospital discharge, up to 1 year

Total amount (micrograms) of Levophed required.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Amount of Vasopressor Required
540 Micrograms
Interval 390.0 to 1100.0
890 Micrograms
Interval 620.0 to 1650.0

SECONDARY outcome

Timeframe: Start of operation through hospital discharge, up to 1 year

Population: The analysis population includes only participants who received vasopressors. Participants who did not receive vasopressors were excluded from this analysis.

Duration (minutes) of vasopressor administration.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=36 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=35 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Duration of Vasopressor Administration
139.5 Minutes
Interval 65.25 to 333.75
219 Minutes
Interval 60.0 to 321.5

SECONDARY outcome

Timeframe: Day of admission through postoperative day 30

Population: The denominator reflects the number of participants with available data for this outcome. Participants with missing postoperative complication data were not included in the analysis. In addition, for 30-day outcomes, participants who remained hospitalized at day 30 were not included because these post-discharge outcomes were not applicable.

Number of participants with postoperative complications (Maryland Hospital Acquired Conditions).

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Number Participants With Postoperative Complications
Unscheduled clinic visits
1 Participants
0 Participants
Number Participants With Postoperative Complications
Emergency Room visits
1 Participants
5 Participants
Number Participants With Postoperative Complications
Outpatient narcotic refills
1 Participants
3 Participants

SECONDARY outcome

Timeframe: Up to 1 year

Population: Participants with collected data.

Total Direct Cost (Pharmacy and equipment costs, professional fees and the dollar-value of total OR time required for administration of each intervention)

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=45 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Total Direct Cost of TEA Placement and LB Surgical Site Infiltration
1168.6 U.S. Dollars
Interval 868.6 to 1334.6
670.5 U.S. Dollars
Interval 604.3 to 725.7

SECONDARY outcome

Timeframe: Postoperative day 14

Population: Participants with collected data.

Patient reported total outpatient narcotic use in IV morphine (mg) equivalents on nurse phone survey administered on postoperative day 14.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=45 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=43 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Post-discharge Narcotic Utilization
22.5 PO Morphine Milligram Equivalents
Interval 0.0 to 75.0
7.5 PO Morphine Milligram Equivalents
Interval 0.0 to 46.25

SECONDARY outcome

Timeframe: Up to 30 days post discharge from index admission

Population: Participants with data collected.

Number of participants with 30-day hospital readmission assessed as the number of participants who get readmitted within 30 days of discharge from the initial admission.

Outcome measures

Outcome measures
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=47 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=49 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Number of Participants With 30-day Hospital Readmission
3 Participants
6 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Serum ACTH level in pg/mL.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

ADH level in pg/mL.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

ANP level in pg/mL.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

TNF-α level in pg/mL.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Baseline and postoperative day 7

Outcome measures

Outcome data not reported

Adverse Events

Arm 1: Thoracic Epidural Analgesia With Bupivicaine

Serious events: 0 serious events
Other events: 31 other events
Deaths: 0 deaths

Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine

Serious events: 0 serious events
Other events: 31 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 participants at risk
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance. Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 participants at risk
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons. Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Cardiac disorders
Hypotension
34.7%
17/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
32.0%
16/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
Gastrointestinal disorders
Nausea/Vomiting
20.4%
10/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
28.0%
14/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
Cardiac disorders
Hypertension
8.2%
4/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
8.0%
4/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
Cardiac disorders
Palpitations
8.2%
4/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
8.0%
4/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
Nervous system disorders
Sedation
2.0%
1/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
10.0%
5/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
Hepatobiliary disorders
Hepatitis
6.1%
3/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
10.0%
5/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.

Additional Information

Rebecca Stone

The Johns Hopkins School of Medicine

Phone: 410-955-8240

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place